文献速递胸部肿瘤

纳米级细胞外囊泡DNA在早期非小细胞肺癌突变检测中优于循环游离DNA

Nanoscale extracellular vesicle-derived DNA is superior to circulating cell-free DNA for mutation detection in early-stage non-small-cell lung cancer.
PubMed 文献 · Ann Oncol · 2018-01-01

研究纳入377例已知EGFR突变状态的非小细胞肺癌患者和69例对照,比较纳米级细胞外囊泡来源DNA(nEV-DNA)与循环游离DNA(cfDNA)采用ARMS-PCR检测EGFR突变的效能。早期NSCLC中nEV-DNA检测灵敏度25.7%、特异度96.6%,cfDNA灵敏度14.2%、特异度91.7%;晚期两者灵敏度均约80%、特异度均超95%。结论:早期NSCLC中nEV-DNA优于cfDNA,晚期优势消失。

要点

  • 早期NSCLC中nEV-DNA检测EGFR突变灵敏度25.7%,高于cfDNA的14.2%。
  • 晚期NSCLC中nEV-DNA与cfDNA灵敏度均约80%,特异度均超95%。
  • nEV-DNA与cfDNA水平均与肿瘤体积无强相关,两者间也无相关性。

核心结论

  • 采用ARMS-PCR检测EGFR突变时,nEV-DNA在早期非小细胞肺癌中优于cfDNA,但该优势在晚期非小细胞肺癌中消失。

研究设计与样本

  • 研究纳入377例已知EGFR突变状态的非小细胞肺癌患者和69例对照,分别获取nEV-DNA和cfDNA。
  • 采用基于扩增阻滞突变系统的PCR(ARMS-PCR)检测EGFR E19del/T790M/L858R突变状态。

主要发现

  • nEV-DNA与cfDNA水平均与肿瘤体积无强相关性,且cfDNA与nEV-DNA水平之间无相关性。
  • 早期非小细胞肺癌中,nEV-DNA检测灵敏度为25.7%、特异度为96.6%,cfDNA灵敏度为14.2%、特异度为91.7%。
  • 晚期非小细胞肺癌中,nEV-DNA与cfDNA灵敏度均约80%,特异度均超过95%。

关键数值与推荐

  • 早期NSCLC:nEV-DNA灵敏度25.7%、特异度96.6%;cfDNA灵敏度14.2%、特异度91.7%。
  • 晚期NSCLC:nEV-DNA与cfDNA灵敏度均约80%,特异度均超过95%。

临床怎么用

  • 在早期非小细胞肺癌患者中,若需无创检测EGFR突变,nEV-DNA的ARMS-PCR检测灵敏度优于cfDNA。
  • 在晚期非小细胞肺癌中,nEV-DNA与cfDNA检测效能相近,均可考虑用于EGFR突变检测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The comparison between relatively intact nanoscale extracellular vesicle-derived DNA (nEV-DNA) and fragmented circulating cell-free DNA (cfDNA) in mutation detection among patients with non-small-cell lung cancer (NSCLC) has not been carried out yet, and thus deserves investigation. PATIENTS AND METHODS: Both nEV-DNA and cfDNA was obtained from 377 NSCLC patients with known EGFR mutation status and 69 controls. The respective EGFRE19del/T790M/L858R mutation status was interrogated with amplification-refractory-mutation-system-based PCR assays (ARMS-PCR). RESULTS: Neither nEV-DNA nor cfDNA levels show a strong correlation with tumor volumes. There is no correlation between cfDNA and nEV-DNA levels either. The detection sensitivity of nEV-DNA and cfDNA using ARMS-PCR in early-stage NSCLC was 25.7% and 14.2%, respectively, with 96.6% and 91.7% specificity, respectively. In late-stage NSCLC, both nEV-DNA and cfDNA show ∼80% sensitivity and over 95% specificity. CONCLUSIONS: nEV-DNA is superior to cfDNA for mutation detection in early-stage NSCLC using ARMS-PCR. However, the advantages vanish in late-stage NSCLC.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Wan Y, Liu B, Lei H, et al. Nanoscale extracellular vesicle-derived DNA is superior to circulating cell-free DNA for mutation detection in early-stage non-small-cell lung cancer. Ann Oncol. 2018. PMID: 30339193. doi:10.1093/annonc/mdy458

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。